JP2017518071A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518071A5
JP2017518071A5 JP2017508762A JP2017508762A JP2017518071A5 JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5 JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5
Authority
JP
Japan
Prior art keywords
chain
chimeric antigen
antigen receptor
seq
specific multi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017508762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059523 external-priority patent/WO2015166056A1/en
Publication of JP2017518071A publication Critical patent/JP2017518071A/ja
Publication of JP2017518071A5 publication Critical patent/JP2017518071A5/ja
Pending legal-status Critical Current

Links

JP2017508762A 2014-05-02 2015-04-30 Cs1特異的多重鎖キメラ抗原受容体 Pending JP2017518071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987805P 2014-05-02 2014-05-02
US61/987,805 2014-05-02
PCT/EP2015/059523 WO2015166056A1 (en) 2014-05-02 2015-04-30 Cs1 specific multi-chain chimeric antigen receptor

Publications (2)

Publication Number Publication Date
JP2017518071A JP2017518071A (ja) 2017-07-06
JP2017518071A5 true JP2017518071A5 (https=) 2018-06-14

Family

ID=53052850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508762A Pending JP2017518071A (ja) 2014-05-02 2015-04-30 Cs1特異的多重鎖キメラ抗原受容体

Country Status (5)

Country Link
US (2) US20170051037A1 (https=)
EP (2) EP3524616A1 (https=)
JP (1) JP2017518071A (https=)
AU (1) AU2015254595B2 (https=)
WO (1) WO2015166056A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
BR112017011893A2 (pt) * 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US11951131B2 (en) 2018-07-03 2024-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SLAMF7 chimeric antigen receptors
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Bcmaと結合する二量体抗原受容体(dar)
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
WO2021260696A1 (en) * 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116949099B (zh) * 2023-07-12 2024-04-02 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9982251B2 (en) 2003-03-14 2018-05-29 Cellectis S.A. Large volume ex vivo electroporation method
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
PT2301576E (pt) * 2004-03-29 2012-12-20 Abbott Biotherapeutics Corp Utilização terapêutica de anticorpos anti-cs1
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 t 세포의 조작 방법
CN104769103B (zh) * 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途

Similar Documents

Publication Publication Date Title
JP2017518071A5 (https=)
JP2017519502A5 (https=)
JP2017522893A5 (https=)
JP2021087455A5 (https=)
JP2020114264A5 (https=)
JP2020511136A5 (https=)
JP2022113880A5 (https=)
JP2017524367A5 (https=)
JP2021094037A5 (https=)
JP2019527557A5 (https=)
FI4324851T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP2020513754A5 (https=)
JP2018508219A5 (https=)
JP2025065142A5 (https=)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2020517295A5 (https=)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2021525524A5 (https=)
JP2019527537A5 (https=)
JP2016514462A5 (https=)
JP2019523301A5 (https=)
JP2016534717A5 (https=)
JP2017513478A5 (https=)
JP2021500881A5 (https=)
JP2020513829A5 (https=)